The primary objectives of this core, the Anatomic and Functional Imaging Core, are to provide P01 projects with an extensive array of research-based imaging technologies; the support of a sophisticated core of highly trained professional imaging physicians, scientists, and technologists; and the database maintenance and data correlation support required to pursue research aimed at improving multiple myelosis (MM) diagnosis, prognosis, and treatment through clinical and preclinical research. These objectives will be met through the accomplishment of the following specific aims:
Specific Aim 1. Offer anatomic and functional imaging for myeloma patients and animal models. The core will bring together state-of-the-art anatomic and functional imaging resources to provide the specific imaging capabilities necessary to enable each P01 project to accomplish its individual aims. This impressive technological support will be delivered by a dedicated team of 2 radiologists with extensive institutional support and the assistance of consultants and collaborators who are world-renown in the modalities used.
Specific Aim 2. Perform guided biopsies providing rapid and accurate visual assessment of disease distribution in patients and animal models, in the skeletal system, and in soft tissues. This service will allow investigators to identify the most metabolically active regions (sentinel lesions).
Specific Aim 3. Maintain and correlate databases from anatomic and functional imaging studies. Core B will continue to maintain databases (i.e., MRI scans, skeletal surveys, fluorodeoxyglucose (FDG) PET scans, CT findings, etc.) already in use during the current funding cycle, and establish new databases as needed. Databases contain quantitative results of each finding that the professional imaging specialists feel is relevant for the modality involved. These databases are periodically converted to an Excel spreadsheet format and e-mailed to Cancer Research and Biostatistics providers for data analysis and correlation, a process that has already resulted in many new insights into the biological behavior of multiple myeloma. Thus, by providing anatomic and functional imaging, as well as database management and correlation with clinical data, Core B will enable P01 projects to pursue research aimed at improving MM diagnosis, prognosis, and treatment through clinical and preclinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-12
Application #
7278222
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
12
Fiscal Year
2006
Total Cost
$102,925
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535

Showing the most recent 10 out of 290 publications